Rossari Biotech Intrinsic Value
Rossari Biotech (ROSSARI) median intrinsic value is ₹951.43 from 10 valuation models (range ₹147–₹1212), vs current price ₹489.80 — +94.2% upside (Trading Below Calculated Value), margin of safety 48.5%. Analyse Rossari Biotech ownership pattern to track promoter, FII and institutional holdings.
ROSSARI Valuation Methods Summary — DCF, Graham Number & P/E
Rossari Biotech intrinsic value across 10 models vs current price ₹489.80 — upside/downside and value range per method. Read Rossari Biotech dividend policy for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹398.40 | ₹318.72 - ₹478.08 | -18.7% | EPS: ₹33.20, Sector P/E: 12x |
| Book Value Method | asset | ₹1211.82 | ₹1090.64 - ₹1333.00 | +147.4% | Book Value/Share: ₹1211.82, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹979.60 | ₹881.64 - ₹1077.56 | +100.0% | Revenue/Share: ₹2560.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹979.60 | ₹881.64 - ₹1077.56 | +100.0% | EBITDA: ₹388.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹802.65 | ₹642.12 - ₹963.18 | +63.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹212.48 | ₹191.23 - ₹233.73 | -56.6% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹273.57 | ₹246.21 - ₹300.93 | -44.1% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹979.60 | ₹881.64 - ₹1077.56 | +100.0% | ROE: 13.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹951.43 | ₹856.29 - ₹1046.57 | +94.2% | EPS: ₹33.20, BVPS: ₹1211.82 |
| Dividend Yield Method | dividend | ₹146.94 | ₹132.25 - ₹161.63 | -70.0% | DPS: ₹0.50, Target Yield: 3.5% |
ROSSARI Intrinsic Value vs Market Price — All Valuation Models
Rossari Biotech fair value range ₹147–₹1212 vs current market price ₹489.80 across 10 valuation models. For current market price and key ratios, visit Rossari Biotech stock price NSE.
ROSSARI Intrinsic Value Analysis — Undervalued or Overvalued?
Rossari Biotech median intrinsic value ₹951.43, current price ₹489.80 — Trading Below Calculated Value by 94.2%, margin of safety 48.5%.
What is the intrinsic value of ROSSARI?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Rossari Biotech (ROSSARI) is ₹951.43 (median value). With the current market price of ₹489.80, this represents a +94.2% variance from our estimated fair value.
The valuation range spans from ₹146.94 to ₹1211.82, indicating ₹146.94 - ₹1211.82.
Is ROSSARI undervalued or overvalued?
Based on our multi-method analysis, Rossari Biotech (ROSSARI) appears to be trading below calculated value by approximately 94.2%.
ROSSARI Financial Health — Key Ratios vs Industry Benchmarks
Rossari Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.45 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.23x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ROSSARI Cash Flow Quality — Operating & Free Cash Flow
Rossari Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹65 Cr | ₹-45 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹137 Cr | ₹46 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹43 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹152 Cr | ₹62 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹29 Cr | ₹-121 Cr | Positive Operating Cash Flow | 6/10 |